Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy

Emily O’Reilly1 Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland

Deborah Casey1 Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland

Hisham Ibrahim1 Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland

Alice McGrath1 Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland

Tomás McHugh1 Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland

Punitha Vairamani1 Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland

Jill Murphy1 Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland

Barry Plant1 Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland;2 Health Research Board Clinical Research Facility, University College Cork, Cork, Ireland

Desmond M Murphy1 Department of Respiratory Medicine, Cork University Hospital, Cork, Ireland;2 Health Research Board Clinical Research Facility, University College Cork, Cork, IrelandCorrespondence[email protected]

show all

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy

Articles from other publishers (2)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy

Citations (2)

Articles from other publishers (2)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date